Healthy Volunteers Clinical Trial
Official title:
A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of Medicinal Product With a Period of Open Safety Assessment in Two Modes of Administration, in Healthy Volunteers
The aim of the present study is at the first stage: a comparative assessment of the safety of the two methods of vaccine administration, at the second - an assessment of the safety and state of post-vaccination immunity at different times after vaccination
Status | Completed |
Enrollment | 224 |
Est. completion date | July 31, 2020 |
Est. primary completion date | June 30, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria - Men and women aged 18 to 55 years old. - Written informed consent. - consent to the use of effective contraceptive methods throughout the study period * * using one of the following methods: abstinence, condoms (male or female with or without spermicide), diaphragm or cervical cap with spermicide, intrauterine device - body mass index (BMI) from 18.5 to 30. - absence of acute infectious diseases or exacerbation of chronic infections at the time of vaccination and 7 days before vaccination; - absence of allergic diseases of a serious degree (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum sickness) - absence of strong post-vaccination reactions or post-vaccination complications for previous use of immunobiological drugs; - absence of pathology from the gastrointestinal tract, liver, kidneys, cardiovascular system, central nervous system, musculoskeletal system, genitourinary and endocrine systems, which may influence the evaluation of the results of the study, in the anamnesis and also according to the screening examination data; - negative pregnancy test (for fertile women); - negative tests for HIV, hepatitis B and C, syphilis; - negative urine test for traces of drugs; - negative test for alcohol content in the exhaled air; - absence of malignant blood diseases; - absence of malignant neoplasms; - indicators of the total blood test at the screening not higher/lower than 1.1 x LLN/ULN (upper/lower limit of the normal reference range) *; * normal reference values of the laboratory performing the studies must be provided before the volunteer screening begins - according to the biochemical blood test at the screening: the level of urea, creatinine, alanine aminotransferase, aspartate aminotransferase, glucose, creatine phosphokinase, total protein, bilirubin, glucose, LDH, alkaline phosphatase, LDL / HDL / VLDL - no higher/lower 1.1 X LLN/ULN (upper/lower limit of the normal reference range), total cholesterol level from 3,6 mmol/l to 7,8 mmol/l; - no changes in myocardium of inflammatory or dystrophic nature according to ECG results at screening; - lack of vaccination against influenza within 6 months before the start of the study (including during participation in other clinical trials). Exclusion criteria - participation of a volunteer in any other study in the last 90 days; - any vaccination in the last 30 days; - vaccination against influenza within 6 months before the start of the study (including during participation in other clinical trials). - symptoms of respiratory illness in the last 3 days; - recent frequent nasal bleeding (> 5 last year); - chronic rhinitis, the presence of defects of the nasal septum, polyps of the nose or other significant anomalies; - surgical operations or a history of nasal trauma for 6 months. - treatment with steroids in the last 10 days; - administration of immunoglobulins or other blood products for the last 3 months; - taking immunosuppressive drugs and / or immunomodulators within 6 months before the start of the study; - regular past or current use of narcotic drugs; - pregnancy or breastfeeding; - systolic blood pressure less than 100 mmHg or higher than 139 mmHg; diastolic blood pressure less than 60 mmHg. or above 90 mmHg; the heart rate is less than 60 beats per minute or more than 90 beats per minute; - exacerbation of allergic diseases, the presence of anaphylactic reactions or angioedema in medical history; - hypersensitivity or allergic reactions to the administration of any vaccine in medical history; - allergic reactions to vaccine components; - diabetes mellitus or other forms of impaired glucose tolerance; - the presence of a concomitant disease that may influence the evaluation of the results of the study: active forms of tuberculosis, chronic liver and kidney diseases, severe thyroid dysfunction and other endocrine system diseases (diabetes mellitus), severe deseases of hematopoietic system, epilepsy and other CNS diseases, myocardial infarction, myocarditis, endocarditis, pericarditis, coronary heart disease, autoimmune pathology, serious chronic diseases requiring a hospitalisation; - donor blood donation (450 ml and more blood or plasma) less than 2 months before the start of the study; - taking a history of more than 5 units of alcohol (equal 0.25 liters of ethanol) per week; - smoking: more than 10 cigarettes a day; - planned hospitalization and / or surgical intervention during the study period, and 4 weeks before the expected date of vaccination. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Federal state budgetary institution " Main military clinical hospital named after academician N. N. Burdenko " of the Ministry of Defence of the Russian Federation | Moscow |
Lead Sponsor | Collaborator |
---|---|
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Main military clinical hospital named after academician N. N. Burdenko |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Adverse Events | Determination of Number of Participants With Adverse Events | through the whole study, an average of 180 days | |
Primary | Antibody levels a measured by an enzyme-linked immunosorbent assay (ELISA) | Determination of antibody levels measured by an ELISA vs. baseline values and vs placebo | through the whole study, an average of 90 days | |
Secondary | Assessment of antigen-specific cell-mediated immune response | determination of specific T-cell- mediated response vs. baseline values ans vs placebo | at days 0 and 7 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |